ScinoPharm Newsroom

	The ScinoPharm Advantage

	Senior Management

	News, Press Releases, and Press Coverage

	Highlights and Media

	Careers

	Contact ScinoPharm

<- Back to Newsroom

Tuesday, September 8, 2005

European Commission Approves Medtronic Endeavor(TM) Drug-Eluting Coronary Stent System for Angioplasty Procedures

TAINAN, Taiwan, Sept. 5 /Xinhua-PRNewswire/ -- ScinoPharm Taiwan reported today that Medtronic's Endeavor(TM) Drug-Eluting Coronary Stent System has been approved for marketing in Europe for the treatment of coronary artery disease during percutaneous coronary interventional procedures. The Endeavor(TM) stent combines Abbott's patented drug Zotarolimus (formerly ABT-578), Medtronic's Driver(R) Coronary Stent platform, and Biocompatibles PC(TM) Polymer into a drug-eluting stent system. The Zotarolimus manufacturing process has been co-developed by Abbott and ScinoPharm, and ScinoPharm will continue to supply the drug substance for the Endeavor(TM) stent. This is the first new chemical entity manufactured by ScinoPharm Taiwan to be included in a commercialized product.

Drug-eluting stents have been shown to be superior to traditional bare- metal stents and can reduce the rate of repeat procedures due to re-clogging of arteries in patients with coronary disease. The worldwide market for drug- eluting stents is approximately $5.5 billion, and is expected to grow at rapid pace. The size of the market outside of the United States, excluding Japan, is between $ 1 billion and $1.5 billion.

ScinoPharm Taiwan, Ltd. offers a wide array of process R&D services and API manufacturing capabilities designed to satisfy customer's exact requirements and facilitate their rapid market introductions. ScinoPharm specializes in process R&D and the production of CGMP Active Pharmaceutical Ingredients (APIs). Additional information is available on the company's WEB site at http://www.scinopharm.com.